CN1369307A - Composite Chinese medicine for treating heptic fibrosis and cirrhosis due to hepatitis B and its mfg. method - Google Patents
Composite Chinese medicine for treating heptic fibrosis and cirrhosis due to hepatitis B and its mfg. method Download PDFInfo
- Publication number
- CN1369307A CN1369307A CN 02114863 CN02114863A CN1369307A CN 1369307 A CN1369307 A CN 1369307A CN 02114863 CN02114863 CN 02114863 CN 02114863 A CN02114863 A CN 02114863A CN 1369307 A CN1369307 A CN 1369307A
- Authority
- CN
- China
- Prior art keywords
- radix
- cordyceps
- chinese medicine
- liver
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 67
- 208000002672 hepatitis B Diseases 0.000 title claims abstract description 20
- 206010016654 Fibrosis Diseases 0.000 title claims abstract description 14
- 230000004761 fibrosis Effects 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 title claims description 31
- 208000019425 cirrhosis of liver Diseases 0.000 title abstract description 12
- 230000007882 cirrhosis Effects 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title abstract 2
- 241000190633 Cordyceps Species 0.000 claims abstract description 36
- 239000000203 mixture Substances 0.000 claims description 53
- 210000000582 semen Anatomy 0.000 claims description 23
- 239000009636 Huang Qi Substances 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 19
- 230000008569 process Effects 0.000 claims description 16
- 241000222336 Ganoderma Species 0.000 claims description 15
- 238000009835 boiling Methods 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 13
- 238000009413 insulation Methods 0.000 claims description 12
- 238000001291 vacuum drying Methods 0.000 claims description 12
- 238000010298 pulverizing process Methods 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 10
- 230000001105 regulatory effect Effects 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 9
- 241000628997 Flos Species 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 5
- 238000004821 distillation Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 235000021419 vinegar Nutrition 0.000 claims description 4
- 239000000052 vinegar Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims 2
- 230000003179 granulation Effects 0.000 claims 2
- 239000000463 material Substances 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 241000219784 Sophora Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 34
- 239000008280 blood Substances 0.000 description 34
- 210000004185 liver Anatomy 0.000 description 31
- 230000000694 effects Effects 0.000 description 29
- 230000001737 promoting effect Effects 0.000 description 17
- 206010019668 Hepatic fibrosis Diseases 0.000 description 15
- 230000017531 blood circulation Effects 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 10
- 210000004024 hepatic stellate cell Anatomy 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229920002674 hyaluronan Polymers 0.000 description 8
- 229960003160 hyaluronic acid Drugs 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 7
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 7
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 241000700721 Hepatitis B virus Species 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000007365 immunoregulation Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 230000008093 supporting effect Effects 0.000 description 4
- 102000002734 Collagen Type VI Human genes 0.000 description 3
- 108010043741 Collagen Type VI Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 240000001592 Amaranthus caudatus Species 0.000 description 2
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 2
- 241000208365 Celastraceae Species 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 101710142246 External core antigen Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 description 2
- 206010019842 Hepatomegaly Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 235000000336 Solanum dulcamara Nutrition 0.000 description 2
- 206010041519 Spider naevus Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000012735 amaranth Nutrition 0.000 description 2
- 239000004178 amaranth Substances 0.000 description 2
- 239000009243 biejia ruangan Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- -1 vacuum drying Substances 0.000 description 2
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 description 1
- YMGFTDKNIWPMGF-AGYDPFETSA-N 3-(3,4-dihydroxyphenyl)-2-[(e)-3-[2-[(e)-2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxypropanoic acid Chemical compound C=1C=C(O)C(O)=C(\C=C\C=2C=C(O)C(O)=CC=2)C=1/C=C/C(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-AGYDPFETSA-N 0.000 description 1
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical group C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 244000173207 Phyllanthus amarus Species 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 241000545442 Radix Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 229940089837 amygdalin Drugs 0.000 description 1
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940099347 glycocholic acid Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 229940040511 liver extract Drugs 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002120 nanofilm Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229930015582 oxymatrine Natural products 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000009923 sugaring Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
The example composition | ????1 | ????2 | ????3 | ????4 | ????5 | ????6 |
?A(g) | ??2000 | ??1500 | ??1200 | ??2000 | ??1750 | ??1650 |
?B(g) | ??1500 | ??1100 | ??1200 | ??1500 | ??1250 | ??1100 |
?C(g) | ??1000 | ??600 | ??600 | ??600 | ??750 | ??1000 |
?D(g) | ??600 | ??550 | ??600 | ??650 | ??750 | ??1000 |
?E(g) | ??300 | ??280 | ??400 | ??250 | ??375 | ??250 |
?F(g) | ??240 | ??100 | ||||
?G(g) | ??100 | ??110 | ??500 | |||
?H(g) | ??100 | ??160 | ??100 | |||
?I(g) | ??150 | ??70 | ||||
?J(g) | ??150 | ??70 | ||||
?K(g) | ??50 | ??150 | ??85 | |||
?L(g) | ??150 | ??110 | ||||
?M(g) | ??100 | ??70 | ||||
?N(g) | ??100 | ??100 | ||||
?O(g) | ??150 | ??100 | ||||
Add up to (g) | ??5400 | ??4480 | ??4400 | ??5750 | ??5780 | ??5500 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02114863 CN1274356C (en) | 2002-02-07 | 2002-02-07 | Composite Chinese medicine for treating heptic fibrosis and cirrhosis due to hepatitis B and its mfg. method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02114863 CN1274356C (en) | 2002-02-07 | 2002-02-07 | Composite Chinese medicine for treating heptic fibrosis and cirrhosis due to hepatitis B and its mfg. method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1369307A true CN1369307A (en) | 2002-09-18 |
CN1274356C CN1274356C (en) | 2006-09-13 |
Family
ID=4743338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02114863 Expired - Fee Related CN1274356C (en) | 2002-02-07 | 2002-02-07 | Composite Chinese medicine for treating heptic fibrosis and cirrhosis due to hepatitis B and its mfg. method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1274356C (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100355447C (en) * | 2005-02-07 | 2007-12-19 | 上海中医药大学附属曙光医院 | Compound preparation for treating liver fibrosis and its preparing method |
CN1977886B (en) * | 2005-12-05 | 2010-05-19 | 山东轩竹医药科技有限公司 | Medicinal composition of oxymatrine, ganoderma lucidum and astragalus |
CN102218104A (en) * | 2010-04-15 | 2011-10-19 | 张立中 | Traditional Chinese medicine preparation for preventing liver fibrosis and treating liver cirrhosis |
CN103356732A (en) * | 2012-03-28 | 2013-10-23 | 泰宗生物科技股份有限公司 | Pharmaceutical composition for preventing and treating hepatic fibrosis or nonalcoholic fatty liver disease |
CN103417675A (en) * | 2013-07-30 | 2013-12-04 | 娄渊贵 | Hepatopathy treatment medicine composition as well as preparation method and usage thereof |
CN104587416A (en) * | 2015-02-17 | 2015-05-06 | 聂玮 | Traditional Chinese medicinal composition for treating early hepatocirrhosis |
CN104826019A (en) * | 2015-05-15 | 2015-08-12 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating hepatitis B with hepatic fibrosis |
WO2020024527A1 (en) * | 2018-08-03 | 2020-02-06 | 上海中医药大学附属曙光医院 | Hepatoprotective traditional chinese medicine composition, extract thereof, and pharmaceutical use thereof |
CN111991540A (en) * | 2020-10-23 | 2020-11-27 | 浙江省中医药研究院 | Traditional Chinese medicine composition for treating hepatic fibrosis and preparation method and application thereof |
CN115025188A (en) * | 2020-06-24 | 2022-09-09 | 博奥生物集团有限公司 | Traditional Chinese medicine for regulating inflammation and/or fibrosis related signal pathway and application thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102836212B (en) * | 2012-08-22 | 2014-10-08 | 芜湖市诺康生物科技有限公司 | Hepatoprotective composition |
-
2002
- 2002-02-07 CN CN 02114863 patent/CN1274356C/en not_active Expired - Fee Related
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100355447C (en) * | 2005-02-07 | 2007-12-19 | 上海中医药大学附属曙光医院 | Compound preparation for treating liver fibrosis and its preparing method |
CN1977886B (en) * | 2005-12-05 | 2010-05-19 | 山东轩竹医药科技有限公司 | Medicinal composition of oxymatrine, ganoderma lucidum and astragalus |
CN102218104A (en) * | 2010-04-15 | 2011-10-19 | 张立中 | Traditional Chinese medicine preparation for preventing liver fibrosis and treating liver cirrhosis |
CN103356732A (en) * | 2012-03-28 | 2013-10-23 | 泰宗生物科技股份有限公司 | Pharmaceutical composition for preventing and treating hepatic fibrosis or nonalcoholic fatty liver disease |
CN103417675A (en) * | 2013-07-30 | 2013-12-04 | 娄渊贵 | Hepatopathy treatment medicine composition as well as preparation method and usage thereof |
CN103417675B (en) * | 2013-07-30 | 2015-03-25 | 娄渊贵 | Hepatopathy treatment medicine composition as well as preparation method and usage thereof |
CN104587416A (en) * | 2015-02-17 | 2015-05-06 | 聂玮 | Traditional Chinese medicinal composition for treating early hepatocirrhosis |
CN104826019A (en) * | 2015-05-15 | 2015-08-12 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating hepatitis B with hepatic fibrosis |
WO2020024527A1 (en) * | 2018-08-03 | 2020-02-06 | 上海中医药大学附属曙光医院 | Hepatoprotective traditional chinese medicine composition, extract thereof, and pharmaceutical use thereof |
CN115025188A (en) * | 2020-06-24 | 2022-09-09 | 博奥生物集团有限公司 | Traditional Chinese medicine for regulating inflammation and/or fibrosis related signal pathway and application thereof |
CN115025188B (en) * | 2020-06-24 | 2023-09-22 | 博奥生物集团有限公司 | Traditional Chinese medicine for regulating inflammation and/or fibrosis related signal pathway and application thereof |
CN111991540A (en) * | 2020-10-23 | 2020-11-27 | 浙江省中医药研究院 | Traditional Chinese medicine composition for treating hepatic fibrosis and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1274356C (en) | 2006-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Levy et al. | Use of herbal supplements for chronic liver disease | |
CN101357219B (en) | Medicine for treating chronic hepatitis B | |
CN1274356C (en) | Composite Chinese medicine for treating heptic fibrosis and cirrhosis due to hepatitis B and its mfg. method | |
CN101716318B (en) | Traditional Chinese medicine preparation for treating tumor of digestive system | |
CN102114099B (en) | Traditional Chinese medicine preparation for inhibiting liver cancer and preparation method thereof | |
CN103536742B (en) | A kind ofly treat pharmaceutical composition of chronic enterogastritis disease and preparation method thereof | |
CN101791385B (en) | Medicine for treating psoriasis | |
CN1709302A (en) | Chinese medicine formulation for treating chronic pelvic inflammation and its preparing method | |
CN116098964B (en) | Traditional Chinese medicine composition for treating thyroid nodule and preparation and application thereof | |
CN100435811C (en) | Apoplexy treating medicine composition | |
CN102188476A (en) | Composition of effective Chinese medicine components for treating hepatic fibrosis | |
CN101698085B (en) | Medicine composite for treating early liver fibrosis or early hepatocirrhosis decompensation, preparation method and application | |
CN100411642C (en) | Medication for treating chronic hepatitis | |
CN103330781A (en) | Traditional Chinese medicine composite with anti-tumor effect and preparation method of injection of same | |
CN102743477B (en) | Traditional Chinese medicine preparation for treating hepatitis and preparation method thereof | |
CN1965897B (en) | Chinese medicinal composition for resisting hepatic fibrosis and method for preparing same | |
CN111228388A (en) | A pharmaceutical composition for treating hepatopathy, and its application method | |
CN108969729A (en) | A kind of Chinese medicine composition and its preparation method and application for treating vascular dementia | |
CN101632829A (en) | Anti-hepatofibrosis traditional Chinese medicament composition, preparation method thereof and medicament preparation | |
CN102058825B (en) | Traditional Chinese medicinal composition for treating hepatitis and preparation method thereof | |
CN103041260B (en) | Chinese medicinal composition for treating acquired immune deficiency syndrome (AIDS) and preparation process | |
CN102233004B (en) | Drug for treating liver diseases | |
CN1247251C (en) | Hyperlipemia treating medicine | |
CN110215474A (en) | A kind of blood-activating and stasis-removing composition and its application | |
TWI444193B (en) | Treatment of liver fibrosis with ethanol-extracted products of achyranthes bidentata |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Suzhou Shenjiu Medpharm Biotech Co., Ltd. Assignor: Ying Tianming Contract fulfillment period: 2009.6.18 to 2014.6.18 contract change Contract record no.: 2009320001450 Denomination of invention: Composite Chinese medicine for treating heptic fibrosis and cirrhosis due to hepatitis B and its mfg. method Granted publication date: 20060913 License type: Exclusive license Record date: 2009.8.10 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.6.18 TO 2014.6.18; CHANGE OF CONTRACT Name of requester: SUZHOU SHENJIU PHARMACEUTICAL BIOTECHNOLOGY CO., L Effective date: 20090810 |
|
ASS | Succession or assignment of patent right |
Owner name: SHENZHEN YINGTIANMING INDUSTRIAL CO., LTD. Free format text: FORMER OWNER: YING TIANMING Effective date: 20101112 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 518003 NO.1, FENGJINGTAI BUILDING, YIJING ROAD, LUOHU DISTRICT, SHENZHEN CITY, GUANGDONG PROVINCE TO: 518003 NO.101, SKIRT BUILDING OF FENGJINGTAI BUILDING, NO.11, YIJING ROAD, LUOHU DISTRICT, SHENZHEN CITY, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20101112 Address after: Luohu District Yijing road Shenzhen city Guangdong province 518003 No. 11 peak Taiwan podium Building No. 101 Patentee after: Shenzhen Yingtianming Industrial Co., Ltd. Address before: 518003 Guangdong city of Shenzhen province Luohu District Yijing Road No. 1 building, Feng Jing Tai Patentee before: Ying Tianming |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060913 Termination date: 20150207 |
|
EXPY | Termination of patent right or utility model |